Author: Parvez, Mohammad K.; Tabish Rehman, Md.; Alam, Perwez; Al-Dosari, Mohammed S.; Alqasoumi, Saleh I.; Alajmi, Mohammed F.
Title: Plant-derived antiviral drugs as novel hepatitis B virus inhibitors: Cell culture and molecular docking study Document date: 2018_12_26
ID: xibqsjib_73
Snippet: In the present study, our in vitro anti-HBV assessment of plantderived non-cytotoxic compounds showed promising inhibitory effects on HBsAg and HBeAg expressions. Of these, quercetin, baccatin III, psoralen, embelin, menisdaurin and azadirachtin showed high anti-HBV activity whereas lupeol, rutin, b-sitosterol and hesperidin had moderate effects. Moreover, a combination of querce-tin with highly active compounds enhanced the therapeutic efficacy......
Document: In the present study, our in vitro anti-HBV assessment of plantderived non-cytotoxic compounds showed promising inhibitory effects on HBsAg and HBeAg expressions. Of these, quercetin, baccatin III, psoralen, embelin, menisdaurin and azadirachtin showed high anti-HBV activity whereas lupeol, rutin, b-sitosterol and hesperidin had moderate effects. Moreover, a combination of querce-tin with highly active compounds enhanced the therapeutic efficacy. This was further supported by in silico molecular docking analysis where all tested anti-HBV molecules strongly interacted with the modeled HBV Pol active site residues. Taken together, our data suggested the novel anti-HBV potential of these natural compounds as viral pol/RT-inhibitors. Nonetheless, further experimental and pre-clinical studies on the most active compounds are warranted.
Search related documents:
Co phrase search for related documents- active compound and highly active compound: 1, 2, 3
- active compound and inhibitory effect: 1, 2
- active compound and natural compound: 1, 2, 3, 4, 5, 6
- active compound and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- active compound and therapeutic efficacy: 1, 2
- active site and anti hbv activity: 1, 2, 3
- active site and anti hbv potential: 1, 2
- active site and docking analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- active site and inhibitory effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active site and natural compound: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- active site and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68
- active site and therapeutic efficacy: 1, 2, 3, 4, 5
- active site residue and inhibitory effect: 1
- active site residue and present study: 1, 2
- anti hbv activity and docking analysis: 1
- anti hbv activity and high anti hbv activity: 1, 2
- anti hbv activity and inhibitory effect: 1, 2
- anti hbv activity and present study: 1
- anti hbv potential and docking analysis: 1
Co phrase search for related documents, hyperlinks ordered by date